Follicular Lymphoma
Pipeline by Development Stage
Drug Modality Breakdown
Follicular Lymphoma is a ~$6.3B market in mature consolidation, dominated by two blockbuster immunomodulators and kinase inhibitors.
Key Trends
- REVLIMID (lenalidomide) faces patent cliff in March 2028, creating biosimilar and generic competition risk
- Next-generation targeted therapies (EZH2 inhibitors, bispecific antibodies) entering peak lifecycle
- CD20-directed antibodies remain foundational but fragmented across multiple rituximab biosimilars
Career Verdict
Solid mid-career opportunity for commercial, medical affairs, and early-stage clinical professionals, but revenue concentration and imminent patent cliff demand strategic positioning.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | REVLIMID (lenalidomide) | Bristol Myers Squibb | $3.9B | 61% | LOE_APPROACHING | Declining | 1.3yr |
| 2 | IMBRUVICA (ibrutinib) | AbbVie | $2.4B | 37% | PEAK | Stable | 8.5yr |
| 3 | TAZVERIK (tazemetostat) | $19M | — | PEAK | Growing | 11.5yr |
Drug Class Breakdown
facing patent cliff 2028
stable peak sales
fragmented, mature
emerging growth
Career Outlook
StableFollicular Lymphoma is a mature, consolidating oncology niche with strong commercial fundamentals but limited growth upside beyond current portfolio. The 2028 REVLIMID patent cliff creates near-term restructuring risk for BMS and opportunity for biosimilar/generic specialists. Hiring remains healthy across commercial and manufacturing, though early-stage clinical and translational roles reflect robust pipeline exploration.
Breaking In
Entry-level professionals should target Commercial or Medical Affairs roles at AbbVie, Roche, or BMS to build hematologic oncology expertise in a well-established disease; avoid R&D entry in this indication due to limited greenfield discovery.
For Experienced Professionals
Mid-to-senior oncology professionals should prioritize positions involving REVLIMID erosion strategy, next-gen mechanism positioning (bispecifics, EZH2i), or global market access in a consolidating but stable franchise.
In-Demand Skills
Best For
Hiring Landscape
6,149 jobs reported across the ecosystem, with Commercial (995) and Manufacturing (448) driving majority of openings. AbbVie (1,118 hiring), Takeda (1,048), and AstraZeneca (1,029) lead company-wide oncology hiring, though only a subset is FL-specific. Average salaries range from $166K (R&D) to $307K (Clinical Operations).
Top Hiring Companies
By Department
Commercial and Manufacturing dominate; highest salaries in Clinical Operations suggest strong demand for late-stage trial and regulatory expertise.
On Market (1)
Approved therapies currently available
Competitive Landscape
38 companies ranked by most advanced pipeline stage
+8 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 7,420 patients across 50 trials
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Dose Optimization Study of Idelalisib in Follicular Lymphoma
To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma
Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)
Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma
Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
A Open-Label Phase in Participants With Multiple Myeloma
Odronextamab in Low Tumor Volume Advanced FL
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Epco, Zanu, Ritux for R/R FL or MZL
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
TGR1202 in Relapsed and Refractory Follicular Lymphoma
A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma
Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma
A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma
Related Jobs in Oncology
US Medical Affairs Lead, Follicular Lymphoma
Manager, Data Science
Senior Manager, Stability Management, Analytical Development and Quality Control
Senior Director, Global Commercial Development
Senior Manager, Customer Engagement Social Strategy and Operations
Senior Talent Acquisition Business Partner
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.